Biospecimens Core (Core-1) Director: Ahmet Dogan, MD, PhD CORE SUMMARY The Biospecimen Core will support the Memorial Sloan Kettering Cancer Center (MSK) SPORE in Lymphoma, which focuses on diffuse large B-cell lymphoma (DLBCL). The overall goal of the Biospecimen core is to provide SPORE investigators with well-characterized biological specimens, including tissues, tissue derivatives, and blood, essential for achieving the aims of the projects. The Biospecimen Core will coordinate tissue acquisition and distribution of high-quality biospecimens by experienced lymphoma pathologists. This shared resource for SPORE investigators will allow for expanding correlative studies, interrogating specific oncogenic signaling pathways, genetic alterations, and biomarker identification.
The Aims of the Biospecimen Core are:
Aim 1. To collect, process, bank, and distribute biospecimens from patients with DLBCL to SPORE investigators and collaborators in support of their research projects.
Aim 2. To provide comprehensive diagnostic characterization of lymphoma specimens collected from patients enrolled on SPORE clinical trials.
Aim 3. To process and perform integral and integrated biomarker analysis on biospecimens collected from patients enrolled on SPORE clinical trials.
|Mondello, Patrizia; Derenzini, Enrico; Asgari, Zahra et al. (2017) Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma. Oncotarget 8:14017-14028|
|Jiang, Yanwen; Ortega-Molina, Ana; Geng, Huimin et al. (2017) CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. Cancer Discov 7:38-53|
|Younes, A; Hilden, P; Coiffier, B et al. (2017) International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol 28:1436-1447|
|Guo, A; Lu, P; Lee, J et al. (2017) HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment. Oncogene 36:3441-3449|
|Giulino-Roth, Lisa; van Besien, Herman J; Dalton, Tanner et al. (2017) Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma. Mol Cancer Ther 16:1779-1790|
|Oricchio, Elisa; Katanayeva, Natalya; Donaldson, Maria Christine et al. (2017) Genetic and epigenetic inactivation of SESTRIN1 controls mTORC1 and response to EZH2 inhibition in follicular lymphoma. Sci Transl Med 9:|
|Grommes, Christian; Younes, Anas (2017) Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis. Cancer Cell 31:731-733|
|Grommes, Christian; Pastore, Alessandro; Palaskas, Nicolaos et al. (2017) Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discov 7:1018-1029|
|Zhang, Jiyuan; Vlasevska, Sofija; Wells, Victoria A et al. (2017) The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma. Cancer Discov 7:322-337|
|Younes, Anas; Berdeja, Jesus G; Patel, Manish R et al. (2016) Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. Lancet Oncol 17:622-31|
Showing the most recent 10 out of 17 publications